Jaguar Health (JAGX) Depreciation and Depletion (2016 - 2017)
Jaguar Health's (JAGX) quarterly Depreciation and Depletion came in at $15031.0 in Q3 2017, little changed year-on-year from $15031.0 in Q3 2016, and little changed on a QoQ basis from $15031.0 in Q3 2016.
Jaguar Health (JAGX) Depreciation and Depletion (2016 - 2017) Analysis & Trends
Jaguar Health (JAGX) has 2 years of Depreciation and Depletion data on file, last reported at $15031.0 in Q3 2017.
- On a quarterly basis, Depreciation and Depletion changed 0.0% year-over-year to $15031.0 in Q3 2017; TTM through Sep 2017 was $43198.0, a 53.36% increase from a year earlier, with the FY2015 full-year figure at $4379.0, changed N/A from the prior year.
- Depreciation and Depletion for Q3 2017 stood at $15031.0, roughly flat from $15031.0 in the prior quarter.
- Over the last five years, Depreciation and Depletion for JAGX reached as high as $15031.0 in Q3 2016 and fell as low as $6568.0 in Q1 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,774.59 Bn | 1,774.53 Bn | - | - |
| 2 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 3 | BeOne Medicines | 473.53 Bn | 468.74 Bn | 1.35 Bn | 39.39 Mn |
| 4 | Vertex Pharmaceuticals | 123.91 Bn | 116.66 Bn | 2.59 Bn | - |
| 5 | Regeneron Pharmaceuticals | 71.79 Bn | 63.04 Bn | 3.31 Bn | - |
| 6 | Belite Bio | 62.15 Bn | 62.15 Bn | - | - |
| 7 | Argenx Se | 54.75 Bn | 49.57 Bn | 1.41 Bn | - |
| 8 | Alnylam Pharmaceuticals | 38.10 Bn | 35.10 Bn | 959.66 Mn | - |
| 9 | Revolution Medicines | 36.11 Bn | 36.11 Bn | - | 2.20 Mn |
| 10 | Jaguar Health | 509,443.80 | -9.55 Mn | 19.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 15,031.00 |
| Sep 30, 2017 | 15,031.00 |
| Sep 30, 2016 | 15,031.00 |
| Sep 30, 2016 | 15,031.00 |
| Jun 30, 2016 | 6,568.00 |
| Jun 30, 2016 | 6,568.00 |
| Mar 31, 2016 | 6,568.00 |
| Mar 31, 2016 | 6,568.00 |